The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group-Reference-Cited by-同舟云学术

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group

Published:2010-10 Issue:10 Volume:34 Page:1330-1335
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Dmoszynska Anna,Walter-Croneck Adam,Hus Iwona,Grzasko Norbert,Manko Joanna,Jedrzejczak Wieslaw Wiktor,Charlinski Grzegorz,Usnarska-Zubkiewicz Lidia,Skotnicki Aleksander,Wolska-Smolen Teresa,Piszcz Jaroslaw,Kloczko Janusz

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Antitumor activity of thalidomide in refractory multiple myeloma;Singhal;N Engl J Med,1999

2. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma;Juliusson;Br J Haematol,2000

3. Thalidomide treatment of resistant or relapsed multiple myeloma patients;Hus;Haematologica,2001

4. Efficacy of a low dose of thalidomide in advanced multiple myeloma;Leleu;Blood,2002

5. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma;Dimopoulos;Hematol J,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia;Slovenian Journal of Public Health;2020-04-06

2. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study;Clinical Lymphoma Myeloma and Leukemia;2020-02

3. Therapy for Relapsed Multiple Myeloma;Mayo Clinic Proceedings;2017-04

4. Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study;Cancer Medicine;2016-12-01

5. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model;Journal of Controlled Release;2016-09